1.A Review of the Method of Performing Pharmacoeconomics Evaluation Using Markov Model and Analysis of Overseas Cases
Xiaomin WAN ; Liubao PENG ; Chongqing TAN ; Xia LUO ; Junhua CAO
China Pharmacy 2005;0(14):-
OBJECTIVE:To fathom the overseas research method for the evaluation of pharmacoeconomics and to improve the development of pharmacoeconomics in China and provide scientific bases for clinical rational use of medicine.METHODS:The research paper abroad introducing the latest therapeutic scheme for breast cancer was taken as an example to expound the method of applying Markov model in the evaluation of pharmacoeconomics.RESULTS & CONCLUSION:Drawing useful experience from abroad about the analytical method and using decision analytic model for the study of pharmacoeconomics are conducive to the development of pharmacoeconomics in China.
2.Studies on the Methods of Cost-utility Analysis for Cholelithiasis Surgery Patients
Liubao PENG ; Chongqing TAN ; Gannong CHEN ; Jianhe LI ; Qiong LU ; Wei CUI ; Yinbo LI
China Pharmacy 2007;0(29):-
OBJECTIVE: To explore a research path and statistical analytical method for cost-utility analysis suitable for gallstone surgery patients.METHODS: A decision-making model for the treatment of cholelithiasis surgery was established;the costs(C) and utility values at each nodal point(? U) were collected,with the results subjected to sensitivity analysis and threshold analysis.RESULTS: The cost-utility ratios(CUR) of laparoscopic operation and open surgery were 4 605.6(? 30%) yuan/QALY and 5 979.7(? 30%) yuan/QALY,respectively.One dimension sensitivity analysis of each( every) parameter reveals that the former CUR value is greater than the latter one.C1 and ? U1 showed the biggest impact on the CUR of laparoscopic operation,while C5 and ? U5 did on the CUR of open surgery.When C1=10 205.6 yuan,or ? U1=1.303 or C5=10 979.8 yuan or ? U5=3.095,CUR of laparoscopic operation was equal to CUR of open surgery,which means that the conversion of threshold was achieved.CONCLUSION: The designed research path and statistic analytic methods are suitable for the cost-utility analysis of cholelithiasis surgery patients.
3.Development and clinical transformation of ninolumab for treatment of non-small cell lung cancer
Chinese Journal of Cancer Biotherapy 2019;26(7):798-801
纳武单抗(nivolumab)为一全人源化IgG4 单克隆抗体靶向PD-1免疫检查点抑制剂,主要通过克服患者体内的免疫抑 制,重新激活免疫细胞来杀伤肿瘤细胞,是一种全新的抗肿瘤理念。纳武单抗作为抗PD-1 受体免疫检查点抑制剂,可通过封闭 T 淋巴细胞的PD-1,阻断其与肿瘤细胞表面PD-L1 结合,解除肿瘤细胞对免疫细胞的抑制,使免疫细胞重新发挥抗肿瘤免疫作用 而杀伤肿瘤细胞。纳武单抗于2015年3月被美国FDA批准治疗铂基治疗进展后转移性鳞状非小细胞肺癌(NSCLC)。7个月后, FDA在同样条件下批准该药物用于非鳞状NSCLC患者。本文主要介绍纳武单抗的药物作用机制、药效学、药动学、临床试验和 安全性等的最新研究进展,为临床用药提供参考。